As new oncology therapeutics progress through the clinic and on to the market, toxicities generated due to the expression of the targets on healthy tissues represent a key concern linked with significant long term morbidities and dramatically reduce the effectiveness of the therapies. The company’s innovative Bi-Cygni® Dual Targeting platform is designed to combat toxicity in cancer treatment.

Acceleris have supported the company from incorporation, advising on the original spin-out then assisting in the introduction of leading investment institutions alongside private SEIS investors. The creativity of this deal was nominated for numerous industry awards.

Patrick Molyneux